<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03093051</url>
  </required_header>
  <id_info>
    <org_study_id>CL005</org_study_id>
    <nct_id>NCT03093051</nct_id>
  </id_info>
  <brief_title>Unpinning Termination Therapy for VT/VF (US)</brief_title>
  <official_title>A Clinical Feasibility Study to Evaluate the Safety and Performance of Low-Energy Unpinning Termination Therapy in Patients With VT/VF</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cardialen, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cardialen, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This observation study evaluates the safety and effectiveness of UPT therapy in subjects
      during either an indicated ventricular tachycardia ablation procedure or an ICD implant
      procedure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This non-blinded, single-arm open-label, non-significant risk, phase 1 pilot, acute research
      feasibility trial aims to demonstrate that the safety and effectiveness of Unpinning
      Termination (UPT) electrotherapy observed in the canine can be translated to humans and to
      demonstrate the safety and effectiveness of UPT electrotherapy in the human population most
      likely to benefit from this therapy. This observation study evaluates the safety and
      effectiveness of UPT therapy in subjects during either an indicated ventricular tachycardia
      (VT) catheter ablation or an indicated initial implant or device replacement of an
      implantable cardioverter defibrillator (ICD).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 12, 2019</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Arrhythmia Termination as assessed by the number of episodes restored to sinus rhythm</measure>
    <time_frame>During study procedure</time_frame>
    <description>To assess the safety and performance of ventricular UPT therapy to terminate ventricular tachyarrhythmias</description>
  </primary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Ventricular Fibrillation</condition>
  <condition>Ventricular Tachycardia</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Unpinning Termination therapy</intervention_name>
    <description>Electrotherapy comprised of standard biphasic and monophasic pacing pulses</description>
    <other_name>Multi-Stage Therapy</other_name>
    <other_name>Multi-Stage Electrotherapy</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        This study will be performed in patients indicated and subsequently undergoing catheter
        ablation of VT/VF or the implant of an implantable cardioverter defibrillator.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Life expectancy of 1 year or greater

          2. Male or female between 18 and 80 years of age

          3. Willing and able to comply with the study protocol, provide a written informed consent

          4. Indication for an endocardial VT catheter ablation for symptomatic VT with use of CESS
             V1.0 or CESS V1.1 OR an indication for an ICD procedure (de novo implant, replacement
             or upgrade) or de novo CRTD procedure for the risk of or presence of VT (CESS 1.0 and
             1.1) and/or VF (CESS 1.1).

          5. Etiology of arrhythmia, or risk of arrhythmia being ischemic cardiomyopathy or
             non-ischemic cardiomyopathy

          6. Medically stable at time of consent to undergo DFT testing performed under general
             anesthesia or conscious sedation as determined by the investigator

        Exclusion Criteria:

        The subject must not meet any of the following exclusion criteria:

          1. Medically unstable at time of study and unsafe to undergo DFT testing under general
             anesthesia or conscious sedation as determined by the investigator

          2. Hemodynamic instability as determined by the investigator

          3. AF or atrial flutter at time of Study Procedure and no anticoagulation for preceding 3
             weeks and no preoperative transesophageal echocardiographic, Cardiac CT or
             Intracardiac echocardiographic confirmation of the absence of LA thrombus

          4. Presence of intracardiac thrombus

          5. Inability to pass catheters to heart due to vascular limitations

          6. Cardiovascular anatomical defects that would complicate placement of the lead or
             catheter required by the protocol, including congenital heart disease and cardiac vein
             anomalies as determined by the investigator

          7. Pregnancy confirmed by test within 7 days of procedure

          8. Presence of a chronically implanted lead in the CS

          9. Presence of a ventricular assist device, including intra-aortic balloon pump

         10. Subjects indicated for VT ablation and experiencing VF with use of CESS V1.0

         11. Subjects requiring the use of inotropes and/or vasopressors for hemodynamic support
             within the 3 days prior to the study.

         12. Prior VT catheter ablation with associated hemodynamic compromise despite pressor
             agents or stroke

         13. Incessant VT/VF or VT/VF storm within six months of scheduled procedure.

         14. LVEF &lt; 20%

         15. New York Heart Association (NYHA) Class IV heart failure

         16. Planned epicardial VT ablation on the same day as the research study

         17. History of hyper-coagulable state that could increase risk of thromboembolic events

         18. History of hemodynamic compromise due to valvular heart disease requiring IV inotropes
             or other circulatory support

         19. Unstable coronary artery disease as determined by the investigator

         20. Severe proximal three-vessel or left main coronary artery disease, without
             revascularization as determined by the investigators

         21. History of embolic stroke, Transient Ischemic Attack or other thromboembolic event in
             the past 6 months

         22. History of Hypertrophic Cardiomyopathy, Arrhythmogenic Right Ventricular Dysplasia,
             Congenital Heart Anomaly, Genetic Cardiac Channelopathy, Cardiac Amyloidosis or
             Cardiac Sarcoidosis.

         23. Cardiovascular surgery or intervention within 1 month prior to enrollment or planned
             for up to 1 month after enrollment (other than the planned treatment procedure)

         24. Morbid obesity: BMI&gt;39 kg/m2

         25. Cognitive or mental health status that would interfere with study participation and
             proper informed consent

         26. Presence of mechanical tricuspid valve

         27. Active Endocarditis

         28. Ventricular arrhythmia with etiology of sarcoid flare

         29. Previously implanted lead is under recall by manufacturer or evidence of lead failure
             as determined by the investigator

         30. End Stage Renal Disease on hemodialysis or peritoneal dialysis, or creatinine
             clearance &lt;15 ml/min

         31. Any other medical condition which may affect the outcome of this study or safety of
             the subject as determined by the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel H Cooper, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dave Munneke, MS</last_name>
    <phone>6128049516</phone>
    <email>DMunneke@cardialen.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tom Rasmussen, BA</last_name>
    <phone>7196596363</phone>
    <email>trasmussen@cardialen.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mills Peninsula Medical Center</name>
      <address>
        <city>Burlingame</city>
        <state>California</state>
        <zip>94010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Milena Ferreira</last_name>
      <email>ferreiml@sutterhealth.org</email>
    </contact>
    <investigator>
      <last_name>Christopher Woods, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mercy Medical Group</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95819</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shelley Allen</last_name>
      <phone>916-453-2626</phone>
      <email>Shelley.allen@dignityhealth.org</email>
    </contact>
    <investigator>
      <last_name>P. Gearoid O'Neill, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Minneapolis VA Healthcare System</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55417</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jill Morgan</last_name>
      <phone>612-467-2455</phone>
      <email>Jill.morgan@va.gov</email>
    </contact>
    <investigator>
      <last_name>Venkatakrishna N Tholakanahalli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janice Amsler</last_name>
      <phone>314-747-8542</phone>
      <email>jmamsler@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Daniel H Cooper, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Gerstl</last_name>
      <phone>919-681-8983</phone>
      <email>Susan.Gerstl@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Brett Atwater, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carrie Nowak</last_name>
      <phone>919-668-3524</phone>
      <email>Carrie.nowak@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Brett Atwater, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashleigh Keiter</last_name>
      <email>Ashleigh.keiter@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>John D Hummel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>OhioHealth Riverside Methodist Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Audrey McDonald</last_name>
      <email>Audrey.McDonald@ohiohealth.com</email>
    </contact>
    <investigator>
      <last_name>Anish Amin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Cardiac Arrhythmia Research Foundation</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deb Cardinal</last_name>
      <phone>512-431-4868</phone>
      <email>dscardinal@austinheartbeat.com</email>
    </contact>
    <investigator>
      <last_name>Andrea Natale, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Janardhan AH, Gutbrod SR, Li W, Lang D, Schuessler RB, Efimov IR. Multistage electrotherapy delivered through chronically-implanted leads terminates atrial fibrillation with lower energy than a single biphasic shock. J Am Coll Cardiol. 2014 Jan 7-14;63(1):40-8. doi: 10.1016/j.jacc.2013.07.098. Epub 2013 Sep 26.</citation>
    <PMID>24076284</PMID>
  </reference>
  <reference>
    <citation>Janardhan AH, Li W, Fedorov VV, Yeung M, Wallendorf MJ, Schuessler RB, Efimov IR. A novel low-energy electrotherapy that terminates ventricular tachycardia with lower energy than a biphasic shock when antitachycardia pacing fails. J Am Coll Cardiol. 2012 Dec 11;60(23):2393-8. doi: 10.1016/j.jacc.2012.08.1001. Epub 2012 Nov 7.</citation>
    <PMID>23141483</PMID>
  </reference>
  <reference>
    <citation>Li W, Janardhan AH, Fedorov VV, Sha Q, Schuessler RB, Efimov IR. Low-energy multistage atrial defibrillation therapy terminates atrial fibrillation with less energy than a single shock. Circ Arrhythm Electrophysiol. 2011 Dec;4(6):917-25. doi: 10.1161/CIRCEP.111.965830. Epub 2011 Oct 6.</citation>
    <PMID>21980076</PMID>
  </reference>
  <reference>
    <citation>Efimov I, Ripplinger CM. Virtual electrode hypothesis of defibrillation. Heart Rhythm. 2006 Sep;3(9):1100-2. Epub 2006 Mar 10.</citation>
    <PMID>16945810</PMID>
  </reference>
  <reference>
    <citation>Ripplinger CM, Krinsky VI, Nikolski VP, Efimov IR. Mechanisms of unpinning and termination of ventricular tachycardia. Am J Physiol Heart Circ Physiol. 2006 Jul;291(1):H184-92. Epub 2006 Feb 24.</citation>
    <PMID>16501014</PMID>
  </reference>
  <reference>
    <citation>Li W, Ripplinger CM, Lou Q, Efimov IR. Multiple monophasic shocks improve electrotherapy of ventricular tachycardia in a rabbit model of chronic infarction. Heart Rhythm. 2009 Jul;6(7):1020-7. doi: 10.1016/j.hrthm.2009.03.015. Epub 2009 Mar 11.</citation>
    <PMID>19560090</PMID>
  </reference>
  <reference>
    <citation>Ambrosi CM, Ripplinger CM, Efimov IR, Fedorov VV. Termination of sustained atrial flutter and fibrillation using low-voltage multiple-shock therapy. Heart Rhythm. 2011 Jan;8(1):101-8. doi: 10.1016/j.hrthm.2010.10.018. Epub 2010 Oct 19.</citation>
    <PMID>20969974</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>March 13, 2017</study_first_submitted>
  <study_first_submitted_qc>March 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 28, 2017</study_first_posted>
  <last_update_submitted>January 9, 2020</last_update_submitted>
  <last_update_submitted_qc>January 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Termination</keyword>
  <keyword>Unpinning</keyword>
  <keyword>Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
    <mesh_term>Ventricular Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

